SCHEMBL27316

SCHEMBL27316

C1CC2CNCC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15193376 1.00
Hydrochloric Acid SCHEMBL2186118 0.96
Hydrochloric Acid SCHEMBL27159005 0.96
SCHEMBL7249921 0.96
Nitric Oxide SCHEMBL7252419 0.90 CHRNB2 (0.46)
SCHEMBL27605 0.86
SCHEMBL4544653 0.86
SCHEMBL14660960 0.86 CHRNB2 (0.42)
SCHEMBL8657415 0.84 CCR5 (0.43)
SCHEMBL2388239 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070278-A Bifunctional protein degradation agent containing aryl substituted heteroaryl and application thereof 标新生物医药科技(上海)有限公司 2026-05-19 CN claimed
EP-4695256-A2 ERBB2 INHIBITORS Cogent Biosciences, Inc. (US) 2026-02-18 EP claimed
US-12479827-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-25 US claimed
EP-4648763-A2 COMPOUNDS FOR FGFRS INHIBITORS Cogent Biosciences, Inc. (US) 2025-11-19 EP claimed
CN-120202200-A Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof 标新生物医药科技(上海)有限公司 2025-06-24 CN claimed
CN-119874616-B Organic intermediate and preparation method and application thereof 四川美域高生物医药科技有限公司 2025-05-30 CN claimed
EP-4547666-A1 METHODS FOR TREATMENT OF CANCER Frontier Medicines Corporation (US) 2025-05-07 EP claimed
CN-119874616-A Novel organic intermediate and preparation method and application thereof 四川美域高生物医药科技有限公司 2025-04-25 CN claimed
US-20250129078-A1 ERBB2 INHIBITORS COGENT BIOSCIENCES, INC. 2025-04-24 US claimed
CN-119768392-A Aryl or heteroaryl substituted glutarimide derivatives and uses thereof 标新生物医药科技(上海)有限公司 2025-04-04 CN claimed
US-6727247-B2 ADENOSINE RECEPTOR LIGANDS IN A METHOD OF TREATMENT, CONTROL, OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS HOFFMAN-LA ROCHE INC. 2004-04-27 US claimed
WO-2004000324-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROPHINES MIMETECH S.R.L. (IT) 2003-12-31 WO claimed
WO-2003087304-A2 TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME BIOGEN, INC. (US) 2003-10-23 WO claimed
US-20030149036-A1 Substituted benzothiazole amide derivatives HOFFMAN-LA ROCHE INC. 2003-08-07 US claimed
WO-2003049741-A1 UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-06-19 WO claimed
US-5707985-A Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators TANABE SEIYAKU CO. LTD. (JP) 1998-01-13 US claimed
EP-0345627-B1 9-R-azacyclic erythromycin antibiotics ABBOTT LAB (US) 1997-04-16 EP claimed
US-5185320-A Antibiotics GRUPPO LEPETIT S.P.A. (IT) 1993-02-09 US claimed
US-5075289-A Improved activity and therapeutic ratios ABBOTT LABORATORIES (US) 1991-12-24 US claimed
EP-0345627-A2 9-R-azacyclic erythromycin antibiotics ABBOTT LABORATORIES (US) 1989-12-13 EP claimed